For the first time, Americans will be able to roll up their sleeves for a seasonal flu shot built on the same mRNA technology that underpinned the COVID-19 vaccines. The US Food and Drug Administration has approved Moderna's mFLUSIVA, also known as mRNA-1010, making it the first licensed mRNA influenza vaccine in the United States and the first non-COVID mRNA vaccine to reach the American market.
The approval, granted on August 5, 2026, covers adults aged 50 and older and arrives ahead of the 2026–2027 respiratory virus season. It marks the arrival of a new platform in routine seasonal immunisation — a shift that public health officials, clinicians and the vaccine industry have anticipated since mRNA technology proved its speed and adaptability during the pandemic, but which until now had never cleared US regulators for influenza.
A milestone that reframes a familiar vaccine
Influenza vaccines are among the oldest and most widely used products in medicine, and for decades they have been manufactured largely in chicken eggs or, more recently, in cell culture. Both approaches require manufacturers to select strains months in advance, grow them, and hope that the circulating viruses do not drift too far from the strains chosen.
mRNA vaccines work differently. Rather than growing a virus or a protein, they instruct the body's own cells to produce a target antigen, prompting an immune response. In practical terms, that can translate into faster design cycles — an attribute that matters enormously for a virus as genetically restless as influenza.
According to the FDA's approval, mFLUSIVA is indicated for active immunisation to prevent influenza disease caused by the influenza A subtypes and influenza B lineages represented in the vaccine. In other words, it is a conventional seasonal flu vaccine in its purpose; what is novel is the platform underneath it.
For Moderna, headquartered in Cambridge, Massachusetts, the decision is also a corporate milestone. The company describes mFLUSIVA as its fifth approved product and its first mRNA-based influenza vaccine. The approval was announced by the company through corporate and investor communications on August 5, 2026.
A split regulatory pathway, split by age
Perhaps the most consequential technical detail of the approval is that it is not uniform across the population it covers. The FDA granted traditional, full approval for adults aged 50 to 64. For adults aged 65 and older, however, the agency granted accelerated approval, a pathway based on immunogenicity data — evidence that the vaccine generates an immune response — rather than on the large-scale clinical outcomes typically required for full approval.
That split is significant, and it is likely to shape how the approval is discussed in clinics and in the pages of medical journals over the next several years. Accelerated approval is a conditional arrangement: it requires the manufacturer to conduct post-marketing confirmatory trials to demonstrate that the immune response translates into real-world protection.
The regulatory logic behind the two-tier decision reflects both the elevated risk that influenza poses to older adults and the practical difficulty of generating definitive efficacy data in that population, where pre-existing immunity, frailty and other factors can complicate trial design. It also reflects a broader debate among regulators and scientists about how much weight to place on immunogenicity as a surrogate marker in a disease where correlates of protection remain imperfectly understood.
The research record does not indicate what specific immunogenicity thresholds were used or how the confirmatory trial will be designed; those details are expected to emerge as Moderna and the FDA publish further documentation.
The advisory committee's role
The approval did not come out of nowhere. On June 18, 2026, the FDA's Vaccines and Related Biological Products Advisory Products Committee, known as VRBPAC, voted unanimously that the benefits of mRNA-1010 outweigh its risks in adults aged 50 to 64 and in adults 65 and older.
The committee's unanimous recommendation was widely cited in subsequent coverage of the final decision and appears to have been a major factor in the agency's reasoning. Advisory committee votes are not binding on the FDA, but a unanimous endorsement — particularly from a panel that has at times been divided over mRNA products — carries substantial weight.
The FDA's review followed a Prescription Drug User Fee Act goal date of August 5, 2026, and the agency met that date, issuing its decision the same day. The BLA approval was recorded in the agency's regulatory communications.
Why older adults are the focus
Influenza is not a uniform threat across the lifespan. Older adults bear a disproportionate share of severe outcomes — hospitalisations, complications from underlying conditions, and deaths — which is why high-dose and adjuvanted flu vaccines have been marketed specifically to this group for years.
Targeting mFLUSIVA at adults 50 and older places it in direct competition with those established products. That competition will unfold not in a vacuum but in the context of long-standing clinical guidelines that recommend annual vaccination for essentially everyone over six months of age, with specific formulations preferred for older recipients.
The research available does not include head-to-head effectiveness comparisons between mFLUSIVA and traditional egg-based or high-dose vaccines. That gap matters. Clinicians choosing between products will want to know whether an mRNA platform offers measurable advantages in the populations most at risk — and that is precisely the question the confirmatory trials are meant to answer.
The evidence question that remains open
Coverage of the approval, according to the research record, has centred on three themes: how the vaccine will be integrated into existing flu-shot campaigns for older adults in the autumn of 2026; how its effectiveness and safety data compare with traditional egg-based and high-dose vaccines; and the conditions attached to the accelerated approval for seniors.
Each of those threads points to the same underlying tension: the regulatory decision is complete, but the evidentiary picture is not. Full approval for the 50–64 group rests on the conventional standard. For the 65-plus group, the agency has effectively said: the immune response is convincing enough to authorise use now, provided you prove the clinical benefit later.
That is a familiar bargain in modern drug regulation. It has accelerated access to treatments for HIV, cancer and rare diseases, and it has also generated controversy when confirmatory trials have lagged or failed. For a vaccine intended for tens of millions of people every year, the stakes of that bargain are unusually broad.
Manufacturing, access and cost — the unanswered questions
The research record does not specify the price of mFLUSIVA, the number of doses Moderna expects to produce for the 2026–2027 season, or how the vaccine will be distributed relative to existing supply chains.
What is clear is that the vaccine is expected to be available in the United States for adults 50 and older during the 2026–2027 flu season, covering the coming autumn and winter. Whether supply will be sufficient to meet demand in the first season, and how insurers and government programmes will treat the product relative to older vaccines, remains to be seen.
Those logistics are not incidental. Seasonal flu vaccination is a mass logistical exercise conducted through pharmacies, clinics, workplaces and public health campaigns, often with overlapping recommendations for COVID-19, RSV and other vaccines. Adding a new platform to that mix — one that may require different storage considerations or different patient counselling — is a system-level challenge as much as a scientific one.
Public-health officials have said that integration into existing campaigns is a central operational question for the coming season, according to the research record.
Different perspectives on the approval
Supporters of the decision point to the speed and flexibility of the mRNA platform, to the unanimous endorsement from the FDA's own advisory committee, and to what the approval signals about the maturation of mRNA technology beyond COVID-19. From this vantage point, mFLUSIVA is less a single product than a proof of concept: if mRNA can be licensed for influenza, the same platform logic can be applied to other seasonal and emerging pathogens.
Sceptics raise different concerns. Some focus on the reliance on immunogenicity rather than clinical outcomes in the 65-plus population, arguing that immune response measurements have historically been an imperfect predictor of how well a flu vaccine actually prevents illness in older adults. Others question whether a new platform is necessary when existing vaccines already provide meaningful — if modest — protection. And some objections are rooted in the broader public debate about mRNA technology that emerged during and after the pandemic.
Both perspectives are likely to feature prominently in the scientific literature and in public discussion over the coming seasons. What neither side can yet claim is definitive real-world comparative data, because that data does not yet exist.
It is worth noting that the research record attributes no direct quotations to FDA officials, Moderna executives or independent scientists. The positions described here reflect the substance of the regulatory decision and the themes identified in contemporaneous coverage, attributed to the organisations involved rather than to individuals.
The global and economic dimension
mFLUSIVA is being watched well beyond the United States. Media and public-health coverage as of early to mid-September 2026 has framed the approval as the first non-COVID mRNA vaccine to reach the US market, expanding the mRNA platform into routine seasonal immunisation — with implications for how other regulators, manufacturers and health systems view the technology.
The economic and geopolitical implications of scaling mRNA flu vaccines have been a running theme. Influenza vaccine manufacturing is a global industry with substantial egg-based capacity, and a shift toward mRNA would redistribute advantage toward companies and countries with mRNA manufacturing infrastructure. The research record flags the broader economic and geopolitical stakes of scale-up without quantifying them.
Major US and international outlets — among them Reuters, ABC News, CNN, NBC News, the Associated Press, Chemical & Engineering News, USA Today and STAT — have covered the approval, reflecting the breadth of interest in what it means for vaccine policy and industry.
What happens next
Three things are now in motion.
First, the rollout. mFLUSIVA is expected to be available for adults 50 and older during the 2026–2027 flu season. How it is positioned in clinical guidance, how it is priced and reimbursed, and how many people actually receive it will determine whether the first season is a proof of demand as well as a proof of concept.
Second, the confirmatory trials. The accelerated approval for adults 65 and older is contingent on post-marketing studies. Those trials will be closely scrutinised — both for their results and for their timing, since delays or inconclusive findings could reopen the regulatory question.
Third, the longer arc. If mRNA influenza vaccines establish themselves, the platform's expansion into routine seasonal immunisation would be a durable legacy of the pandemic-era investment in mRNA science. Whether that expansion happens quickly or gradually will depend less on regulatory milestones than on the accumulated evidence of whether these vaccines protect people better than, or as well as, the alternatives already in the refrigerator.
For now, the FDA's decision is a genuine first: a new class of flu vaccine, cleared for use, arriving just in time for the season it was designed for. What it does not yet come with is the one thing that will ultimately decide its place in medicine — a season's worth of evidence showing how well it works in the people who need it most.